Promotion of an unlicensed medicine by Allergy Therapeutics
Published 14 December 2021
© Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-october-2021/promotion-of-an-unlicensed-medicine-by-allergy-therapeutics
ALK complained to the MHRA about materials disseminated by Allergy Therapeutics about Venomil, an unlicensed medicine available as a ‘special’. The complainant alleged that proactive communication with healthcare professionals and the distribution of material about Venomil constituted the promotion of an unlicensed medicine.
Following review of a letter supplied by Allergy Therapeutics and their assurance that other materials are only supplied to healthcare professionals in response to an unsolicited request, MHRA did not uphold the complaint. Advice was provided on ensuring that no product claims were included in any future materials to be distributed proactively or in response to enquiries.